The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Retrospective registry evaluating the PSA flare phenomenon with cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).
Antoine Angelergues
No relevant relationships to disclose
Florence Mercier
Consultant or Advisory Role - Boston Scientific; Boston Scientific; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; GlaxoSmithKline; GlaxoSmithKline; Sanofi ; Sanofi
Aude Flechon
Honoraria - Sanofi
Aline Guillot
Consultant or Advisory Role - X; X
Sylvestre Le Moulec
No relevant relationships to disclose
Gwenaelle Gravis
Consultant or Advisory Role - Sanofi (U)
Philippe Beuzeboc
Honoraria - Sanofi ; Specific speeches
Christophe Massard
No relevant relationships to disclose
Karim Fizazi
Consultant or Advisory Role - Amgen; Amgen; Amgen; Astellas Pharma; AstraZeneca; Janssen Oncology; Janssen Oncology; Janssen Pharmaceutical ; Keocyt; Keocyt; Keocyt; Novartis; Sanofi ; Sanofi ; Sanofi
Thibault De La Motte Rouge
Consultant or Advisory Role - Sanofi ; Sanofi
Honoraria - Sanofi ; Sanofi
Research Funding - Astellas Pharma; Astellas Pharma; Millennium; Millennium
Reza-Thierry Elaidi
No relevant relationships to disclose
Stephane Oudard
Consultant or Advisory Role - Amgen; Amgen; Bayer; Bayer; Keocyt; Keocyt; Novartis; Novartis; Roche; Roche; Sanofi ; Sanofi
Honoraria - Amgen; Amgen; Bayer; Bayer; Keocyt; Keocyt; Novartis; Novartis; Pfizer; Pfizer; Roche; Roche; Sanofi ; Sanofi